Active	Status	Sponsor type	Region	Phase	Filter
9 Active 3 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Shapiro, Michael
PREVENTABLE, NCT04262206: Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults	Recruiting	4	20000	US	Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet	Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences	Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases	12/26	12/26
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease	Active, not recruiting	3	17004	Europe, Canada, Japan, US, RoW	Inclisiran sodium 300 mg, Placebo	Novartis Pharmaceuticals	Atherosclerotic Cardiovascular Disease	10/27	10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Recruiting	3	14000	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	03/29	03/29
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis	Recruiting	2	502	Europe, Canada, US, RoW	Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo	Novartis Pharmaceuticals	Aortic Stenosis	01/29	01/29
TRIAD, NCT05887414: Appendicitis Decision-making Surveys	Recruiting	N/A	3000	US	Baseline, 30 Day Follow Up	University of Washington, Patient-Centered Outcomes Research Institute	Appendicitis	10/24	10/25
PACT, NCT04100564: LITES Task Order 0005 Prehospital Airway Control Trial	Recruiting	N/A	2009	US	Supraglottic airway device, LMA, King, igel, Standard airway management	Jason Sperry, United States Department of Defense	Trauma Injury, Airway Control	03/25	03/26
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	Recruiting	N/A	7500	US	The Cleerly CAD Staging System	Cleerly, Inc., CPC Clinical Research	Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome	03/29	03/29